Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
MDV3100: AR Heterogeneity in Prostate Cancer Models
2026-09-26
Use MDV3100 (Enzalutamide) to test androgen receptor dependence, pathway suppression, and treatment response in prostate cancer models. Pair drug exposure with AR-status profiling to distinguish sensitive AR-positive cells from AR-low or AR-negative populations that may persist despite treatment.
-
ROCK Inhibition in Organoid-Era Cancer Research
2026-09-25
Patient-derived medulloblastoma organoids create a valuable setting for asking how cytoskeletal signaling shapes tumor behavior. This article considers where Y-27632 could help test those questions, how to design interpretable perturbation studies, and why its role in these models remains a hypothesis to validate—not a finding of the organoid study.
-
Bardoxolone Methyl: Redox Research Workflows
2026-09-25
Use Bardoxolone methyl to probe Nrf2 activation and NF-kB inhibition in oxidative-stress, inflammation, kidney-injury, and cancer models. This guide turns those mechanisms into a practical workflow while showing how to test—rather than assume—a connection to thioredoxin-dependent replication-stress biology.
-
Beyond ATP Competition: Translating VX-702 Biology
2026-09-24
VX-702 offers a precise way to interrogate p38α MAPK signaling across inflammatory and tissue-injury models. This article connects its reported pharmacology with emerging evidence on activation-loop dephosphorylation, then outlines experiments that can separate established inhibitor effects from mechanisms that still need testing.
-
Pifithrin-α Workflows for p53-Linked Ferroptosis
2026-09-24
Use Pifithrin-α (PFTα) to test whether p53 activity contributes to stress-related cell injury—not simply whether a treatment changes viability. This practical guide adapts a maternal deltamethrin neurotoxicity study into a controlled HT-22 workflow, with assay choices and troubleshooting that separate p53-pathway effects from evidence of ferroptosis.
-
Gingerenone A Restores Sunitinib Sensitivity in RCC
2026-09-23
A 2026 study identifies gingerenone A as an LDHA-associated metabolic inhibitor that suppresses glycolysis and weakens HIF-1α/VEGFA/VEGFR2 signaling in renal cell carcinoma. By combining gingerenone A with sunitinib, the researchers observed synergistic effects in cell models and greater tumor-growth suppression in vivo, including in a sunitinib-resistant setting.
-
Parathyroid Hormone (1-34) Human: Assay Design
2026-09-23
Parathyroid hormone (1-34) (human) is a receptor-active tool for connecting cAMP signaling with bone and kidney disease models. This guide emphasizes exposure-pattern control, assay endpoint selection, and the implications of PTH-driven valvular endothelial-to-mesenchymal transition.
-
Amplex Red in Nanoelectrode Biosensing
2026-09-22
Amplex Red is more than a hydrogen peroxide reporter: paired with immobilized HRP, it becomes a functional readout for enzyme activity on nanoscale electrodes. This article connects fluorogenic chemistry with assay design, spatial biosensing, and rigorous interpretation of redox signals.
-
Meropenem Trihydrate and the Metabolomic Resistance Map
2026-09-22
Meropenem trihydrate is more than a broad-spectrum carbapenem antibiotic: used as a defined experimental pressure, it can help translational researchers connect cell-wall pharmacology with the metabolic signatures of carbapenem resistance. This article interprets recent LC-MS/MS evidence and translates it into practical, reproducible research strategy.
-
Amplex Red: ATX Assay Workflow & Optimization
2026-09-21
Learn how Amplex Red converts enzyme-coupled hydrogen peroxide production into a quantitative fluorescence readout for autotaxin inhibitor discovery, ROS studies, and redox biology. This practical guide combines cascade design, screening logic, interference controls, and troubleshooting for reproducible microplate assays.
-
Sitagliptin Phosphate Monohydrate: Assay Logic
2026-09-21
Sitagliptin phosphate monohydrate can do more than establish DPP-4 inhibition in metabolic studies. This article presents a causal assay framework that separates incretin stabilization from intestinal stretch signaling, enabling sharper interpretation of gut–brain and glucose-homeostasis experiments.
-
Salvianolic Acid B Targets LH2 in Pulmonary Fibrosis
2026-09-20
The reference study identifies Salvianolic acid B, also known as Dan Shen Suan B, as a compound that suppresses lysyl hydroxylase 2 expression and reduces pathological collagen remodeling in pulmonary fibrosis models. Its significance lies in connecting LH2-dependent collagen cross-linking with epithelial and fibroblast activation, while providing a practical framework for testing matrix-centered antifibrotic mechanisms.
-
SGI-1027: DNA Methyltransferase Inhibitor Workflow
2026-09-19
SGI-1027 is a DNA methyltransferase inhibitor for linking DNMT1 suppression with promoter demethylation, tumor suppressor gene reactivation, and cancer-cell phenotyping. This workflow combines concentration scouting, molecular readouts, and functional assays to help researchers distinguish epigenetic activity from nonspecific cytotoxicity.
-
PreScission Protease for dKeap1 Condensate Assays
2026-09-18
PreScission Protease combines HRV 3C protease specificity with 4°C cleavage conditions suited to fragile recombinant proteins. This article shows how to remove affinity tags from dKeap1 and related constructs while preserving controls needed to distinguish authentic condensates from tag-driven artifacts.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-09-18
The 2025 study by Oliveira and colleagues shows that naturally occurring angiotensin peptides can increase SARS-CoV-2 spike-protein binding to host receptors, with especially strong effects from shorter or N-terminally modified fragments. Its antibody-based binding design connects renin–angiotensin system biology with viral-entry research while also clarifying that receptor-binding enhancement is not equivalent to demonstrated infection or clinical disease.